背景:本研究的目的是评估在卵巢切除大鼠治疗高脂血症性骨质疏松中,去活肉芽胞苷调节PI3K/AKT信号通路的机制。
方法:我们将无特异性病原体(SPF)大鼠随机分为五组(每组n=10)。正常对照组接受标准饮食,而模型组,阿托伐他汀组,己烯雌酚组,治疗组给予高脂饮食。四周后,进行了双侧卵巢切除术,其次是药物干预。经过6周的治疗,相关指标进行对比分析。
结果:与正常对照组相比,模型组大鼠小梁形态模糊,杂乱无章的骨细胞,骨特异性碱性磷酸酶(BALP)水平显着升高,骨Gla蛋白(BGP),总胆固醇(TC),肿瘤坏死因子-α(TNF-α),和NF-κB受体激活剂配体(RANKL)。此外,模型组显示极限载荷水平显著降低,断裂载荷,雌二醇(E2),骨矿物质密度(BMD),骨保护素(OPG),股骨组织中的磷酸肌醇3-激酶(PI3K)和蛋白激酶B(Akt)。与正常对照组相比,阿托伐他汀组的TC和TNF-α水平更高。相反,治疗组表现出增强的小梁形态,更致密的结构,较小的骨髓腔,减少BALP,BGP,TC,TNF-α,和RANKL水平。此外,治疗组表现出更高水平的E2,BMD,OPG,骨组织中PI3K和Akt与模子组比拟。治疗组的TC和TNF-α水平也低于阿托伐他汀组。生物力学分析表明,在给药后,治疗组的体重减少,股骨的极限载荷和骨折载荷增加,更致密的骨骼结构,较小的骨髓腔,与模型组相比,骨膜排列改变。
结论:我们的研究表明,露天莲在预防和治疗绝经后大鼠高脂血症性骨质疏松症方面具有显着的功效。
BACKGROUND: To aim of this study is to assess the mechanism through which Desertliving
Cistanche modulates the PI3K/AKT signaling pathway in the treatment of hyperlipidemic osteoporosis in ovariectomized rats.
METHODS: We randomly assigned specific-pathogen-free (SPF) rats into five groups (n = 10 per group). The normal control group received a standard diet, while the model group, atorvastatin group, diethylstilbestrol group, and treatment group were fed a high-fat diet. Four weeks later, bilateral ovariectomies were conducted, followed by drug interventions. After six weeks of treatment, relevant indicators were compared and analyzed.
RESULTS: Compared to the normal control group, rats in the model group exhibited blurred trabecular morphology, disorganized osteocytes, significantly elevated levels of bone-specific alkaline phosphatase (BALP), bone Gla-protein (BGP), total cholesterol (TC), tumor necrosis factor-α (TNF-α), and receptor activator of NF-κB ligand (RANKL). Also, the model group revealed significantly reduced levels of ultimate load, fracture load, estradiol (E2), bone mineral density (BMD), osteoprotegerin (OPG), and phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt) in femoral tissue. The atorvastatin group presented with higher TC and TNF-α levels compared to the normal control group. Conversely, the treatment group demonstrated enhanced trabecular morphology, denser structure, smaller bone marrow cavities, and reduced BALP, BGP, TC, TNF-α, and RANKL levels. Furthermore, the treatment group exhibited higher levels of E2, BMD, OPG, and PI3K and Akt in bone tissue compared to the model group. The treatment group also had lower TC and TNF-α levels than the atorvastatin group. Biomechanical analysis indicated that after administration of Desertliving
Cistanche, the treatment group had reduced body mass, increased ultimate and fracture load of the femur, denser bone structure, smaller bone marrow cavities, and altered periosteal arrangement compared to the model group.
CONCLUSIONS: Our study revealed that Desertliving
Cistanche demonstrated significant efficacy in preventing and treating postmenopausal hyperlipidemic osteoporosis in rats.